Shares of PharmaCyte Biotech, Inc. (NASDAQ:PMCB – Get Free Report) fell 0.7% on Tuesday . The company traded as low as $1.05 and last traded at $1.05. 4,460 shares changed hands during trading, a decline of 79% from the average session volume of 21,645 shares. The stock had previously closed at $1.06.
PharmaCyte Biotech Price Performance
The business’s 50-day moving average price is $1.32 and its two-hundred day moving average price is $1.55. The firm has a market cap of $7.21 million, a price-to-earnings ratio of 1.98 and a beta of -0.43.
PharmaCyte Biotech (NASDAQ:PMCB – Get Free Report) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.10) earnings per share for the quarter.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
Recommended Stories
- Five stocks we like better than PharmaCyte Biotech
- What is the Australian Securities Exchange (ASX)
- NVIDIA Stock Surges on Bullish News: How High Could It Climb?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Why Boeing May Be Ready to Take Off After Latest Developments
- 3 Ways To Invest In Coffee, Other Than Drinking It
- eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner?
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
